The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationAMoRe: an automated package for molecular replacement
Navaza, J. (1994) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767393007597 · Cited by 4,953
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationA quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
Kantarjian, H. M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Ossenkoppele, G. J., Nicolini, F.-E., O'Brien, S. G., Litzow, M., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080689 · Cited by 746
Tokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M., Kiefer, S. E., Kish, K., Lee, F. Y. F., Borzillerri, R., Lombardo, L. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4187 · Cited by 700
O'Hare, T., Eide, C. A., & Deininger, M. W. N. (2007) · Blood · doi:10.1182/blood-2007-03-066936 · Cited by 641
Self-citationShah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30890 · Cited by 418
Bradeen, H. A., Eide, C. A., O'Hare, T., Johnson, K. J., Willis, S. G., Lee, F. Y., Druker, B. J., & Deininger, M. W. (2006) · Blood · doi:10.1182/blood-2006-02-004580 · Cited by 393 · cited 2×
“This assay has previously been used to characterize the resistance profile of imatinib, nilotinib, and dasatinib, and has proved to be predictive of clinical experience with these inhibitors (Bradeen et al., 2006).”
MethodResultSelf-citationGiles, F. J., Cortes, J., Jones, D., Bergstrom, D., Kantarjian, H., & Freedman, S. J. (2007) · Blood · doi:10.1182/blood-2006-05-025049 · Cited by 364
Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 313
Cortes, J., Jabbour, E., Kantarjian, H., Yin, C. C., Shan, J., O'Brien, S., Garcia-Manero, G., Giles, F., Breeden, M., Reeves, N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080838 · Cited by 296
Shah, N. P., Kasap, C., Weier, C., Balbas, M., Nicoll, J. M., Bleickardt, E., Nicaise, C., & Sawyers, C. L. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.11.001 · Cited by 230
O'Hare, T., Pollock, R., Stoffregen, E. P., Keats, J. A., Abdullah, O. M., Moseson, E. M., Rivera, V. M., Tang, H., Metcalf, C. A., Bohacek, R. S., et al. (2004) · Blood · doi:10.1182/blood-2004-05-1851 · Cited by 200
Self-citationTherapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia
Quintás‐Cardama, A., & Cortes, J. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0117 · Cited by 102
Crystal Structure of the T315I Mutant of Abl Kinase
Zhou, T., Parillon, L., Li, F., Wang, Y., Keats, J. A., Lamore, S. D., Xu, Q., Shakespeare, W. C., Dalgarno, D. C., & Zhu, X. (2007) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2007.00556.x · Cited by 102
Self-citationKhorashad, J. S., Milojković, D., Mehta, P., Anand, M., Ghorashian, S., Reid, A. G., Melo, V. D., Babb, A., de Lavallade, H., Olavarría, E., et al. (2007) · Blood · doi:10.1182/blood-2007-06-096396 · Cited by 87
O’Hare, T., Eide, C. A., Tyner, J. W., Corbin, A. S., Wong, M. J., Buchanan, S. G., Holme, K. R., Jessen, K. A., Tang, C. M., Lewis, H. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800587105 · Cited by 85
Self-citationTreatment selection after imatinib resistance in chronic myeloid leukemia
Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2009) · Targeted Oncology · doi:10.1007/s11523-008-0100-y · Cited by 56
Huang, W., Zhu, X., Wang, Y., Azam, M., Wen, D. J., Sundaramoorthi, R., Thomas, R. M., Liu, S., Banda, G., Lentini, S. P., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900166t · Cited by 49
Self-citationRosée, P. G. L., Holm-Eriksen, S., Koenig, H., Härtel, N., Ernst, T., Debatin, J., Mueller, M., Erben, P., Binckebanck, A., Wunderle, L., et al. (2008) · Haematologica · doi:10.3324/haematol.12186 · Cited by 41
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors
Wang, Y., Shakespeare, W. C., Huang, W.-S., Sundaramoorthi, R., Lentini, S. P., Das, S., Liu, S., Banda, G., Wen, D., Zhu, X., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.06.042 · Cited by 33
Self-citationStagno, F., Stella, S., Berretta, S., Massimino, M., Antolino, A., Giustolisi, R., Messina, A., Raimondo, F. D., & Vigneri, P. G. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.08.008 · Cited by 13
Cited by
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationSmall molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Metadata
- Authors
- O'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., Metcalf, C. A., Tyner, J. W., Loriaux, M. M., Corbin, A. S., Wardwell, S., Ning, Y., Keats, J. A., Wang, Y., Sundaramoorthi, R., Thomas, M., Zhou, D., Snodgrass, J., Commodore, L., Sawyer, T. K., Dalgarno, D. C., Deininger, M. W. N., Druker, B. J., & Clackson, T.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2009-11
- Volume
- 16
- Issue
- 5
- Pages
- 401-412
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2110648386
- Cited by
- 1,259
- References
- 31
- FWCI
- 37.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.